July 15 (Reuters) – Taiwan-based contract drugmaker Bora Pharmaceuticals will partner with Insilico Medicine on a collaboration aimed at improving efficiency, potentially valued at more than $2.5 billion if fully implemented, the drug discovery firm said on Wednesday. • Collaboration to “explore opportunities” for automation in areas including pharmaceutical development, process optimisation and quality systems, […]
Health
Taiwan’s Bora Pharmaceuticals in potential $2.5 billion collaboration with Insilico Medicine
Audio By Carbonatix
July 15 (Reuters) – Taiwan-based contract drugmaker Bora Pharmaceuticals will partner with Insilico Medicine on a collaboration aimed at improving efficiency, potentially valued at more than $2.5 billion if fully implemented, the drug discovery firm said on Wednesday.
• Collaboration to “explore opportunities” for automation in areas including pharmaceutical development, process optimisation and quality systems, Insilico said in a statement.
• Collaboration expected to apply Insilico capabilities to improve efficiency in manufacturing, supply chain, distribution and corporate operations.
• “Together, we aim to build a scalable and repeatable model that can advance promising drug candidates more efficiently, positioning Bora at the forefront of AI-enabled pharmaceutical development and manufacturing, and establish a long-term growth platform through the development and commercialisation of high-value proprietary assets,” Bora CEO Bobby Sheng said in a statement.
• Insilico has previously announced partnerships with Asia-based drugmakers including China Medical System and Japan’s Takeda Pharmaceutical.
(Reporting by Andrew Silver in Shanghai; Editing by Jacqueline Wong)